Oxford’s Vaccitech raises $110.5 million as it debuts on Nasdaq


Vaccitech Ltd, the Oxford-based clinical-stage biopharmaceutical company behind the Oxford AstraZeneca vaccine, raised $110.5 million on its debut on the Nasdaq Global Market in the US under the ticker symbol “VACC” on April 30, 2021.

Vaccitech was founded in 2016 by Professor Sarah Gilbert and Professor Adrian Hill as a spin out from Oxford University’s Jenner Institute, one of the most prestigious vaccine centres in the world. The company is based at the Oxford Science Park.

Vaccitech’s proprietary platform comprises proprietary modified simian adenoviral vectors, known as ChAdOx1 and ChAdOx2, as well as the well-validated Modified Vaccinia Ankara, or MVA, boost vector, both with demonstrable tolerability profiles and without the ability to replicate in humans.

The company has a broad pipeline of both clinical and preclinical stage therapeutic programs in solid tumors and viral infections and prophylactic viral vaccine programs. Vaccitech co-invented a COVID-19 vaccine with the University of Oxford, now approved for use in many territories and exclusively licensed worldwide to AstraZeneca through Oxford University Innovation, or OUI. Vaccitech is entitled to receive a share of the milestones and royalty income received by OUI from AstraZeneca.